

Talanton Announces Strategic Investment in Pharmakina to Combat Malaria and Strengthen Pharmaceutical Self-Sufficiency in Africa

NEWTOWN SQUARE, Pa. | January 30, 2026 — Talanton, a U.S.-based faith-driven impact investment fund, is pleased to announce a strategic investment in Pharmakina S.A., ***Africa's only producer of quinine-based malaria treatments and the world's only vertically integrated quinine manufacturer.***

This partnership marks a significant step toward expanding access to life-saving medicines, advancing pharmaceutical resilience, and generating meaningful employment for communities across the region.

Advancing Life-Saving Access in a Region of Unmet Need

Malaria remains one of the most devastating public health challenges in Africa, causing 597,000 deaths globally in 2023, with 95% occurring within the region and 76% among children under five. The World Health Organization warns that ongoing disruptions to prevention and treatment efforts could result in 15 million additional cases and over 100,000 additional deaths each year if action is not taken.

Against this backdrop, Pharmakina plays a uniquely critical role. The company delivers over 7 million malaria treatment courses annually, ensuring affordable quinine reaches vulnerable populations where alternatives are either cost-prohibitive or inaccessible. As the only producer of quinine API and finished pharmaceutical products fully integrated within sub-Saharan Africa, Pharmakina is positioned as a stabilizing force in an essential medicine supply chain.

Operational Strength and Regional Impact

Pharmakina's model extends far beyond pharmaceutical output. The company employs 870 workers, partners with 2500+ smallholder farmers, and provides steady, dignified income opportunities in a region where formal employment options are scarce. Its integrated agronomy program supports farmers through disease-resistant seedlings, training, and sustainable agroforestry approaches—strengthening both livelihoods and ecosystems.

Despite operating in one of the most challenging environments in the region, Pharmakina's resilience is notable. In recent performance, the company posted strong operational achievements, including:

- YTD 2025 achieving \$13 million in revenue with 30% sales growth while maintaining profitability
- YTD 24% growth in domestic market sales over the same period in 2024
- YTD 123% increase in export revenue compared to the same period in 2024
- YTD Distribution of 2.34 million seedlings to smallholder farmers, expanding long-term supply sustainability by developing an outgrower cinchona bark supply strategy

This combination of operational discipline, community partnership, and mission-driven resilience underscores why Talanton views Pharmakina as a transformational enterprise.

Scaling Capacity for Long-Term Transformation

Talanton's investment supports Pharmakina's next phase of expansion, focused on increasing production capacity, modernizing equipment, and strengthening regional pharmaceutical self-sufficiency. Planned upgrades include:

- Expanding API extraction capacity from 2'500 MT to 5'000 MT
- Modernizing manufacturing lines and upgrading safety and efficiency systems
- Scaling pharmaceutical production to meet demand across Africa
- Enhancing R&D and the world's first SAH Ex-Vitro rapid multiplication greenhouse for quinine, enabling 1.3 million seedlings annually by 2026

These improvements will allow Pharmakina to serve more patients across more countries, reduce reliance on imported essential medicines, and strengthen long-term access to affordable malaria treatment.

A Shared Vision for Hope and Human Flourishing

"Pharmakina is delivering life-saving medicines while creating dignified work and stability in a region that needs both urgently," said Jon Halverson, Partner at Talanton. "We believe their leadership, resilience, and community commitment make them one of the most strategically important companies in the fight against malaria in Africa."

"We are honoured to welcome Talanton into Pharmakina's family. We see much more than obvious business opportunities but an alignment in our vision of helping Africa to become self-sustainable in providing for itself with its own resources and have a positive impact on thousands of our African brothers and sisters." Roland Decorvet - Chairman, Pharmakina

Talanton's investment further advances its mission to create jobs, bring Hope, and transform lives, reflecting a deep commitment to partnering with values-aligned enterprises that drive social, economic, and spiritual impact.

About Talanton

Talanton is a faith-driven private investment fund dedicated to creating jobs, bringing Hope, and transforming lives through growth-stage businesses in sub-Saharan Africa. Through rigorous due diligence and hands-on post-investment support, Talanton invests in companies that empower communities and strengthen regional resilience. Learn more at www.talantonimpact.com.

About Pharmakina

[Pharmakina](#) is a leading pharmaceutical manufacturer serving Africa and one of the world's primary producers of quinine-based malaria treatments. Through its vertically integrated production model, sustainable agronomy programs, and partnerships with smallholder farmers, Pharmakina delivers essential medicines while driving economic opportunity and environmental stewardship.

